28.8 C
New York
Sunday, June 14, 2026

Tag: infection

New Bass Center Clinic and Infusion Center to Facilitate Healing

PALO ALTO, Calif., July 15, 2025 /PRNewswire/ -- Lucile Packard Children's Hospital Stanford, the cornerstone of Stanford Medicine Children's Health, is proud to announce...

Study examines safety, cost, and environmental tradeoffs of re-using versus discarding medical devices

ECRI assessed evidence surrounding single-use vs. reprocessed medical devices in hospitals WILLOW GROVE, Pa., July 14, 2025 /PRNewswire/ -- One way healthcare providers attempt to reduce...

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society’s Annual...

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also...

Future Healthcare Champions Encouraged to Apply for the Dr. Sagy Grinberg Healing Hands Scholarship

An Award to Support Undergraduate Students Pursuing Careers in Health and Medicine
An Award to Support Undergraduate Students Pursuing Careers in Health and Medicine

SIFI Announces Reimbursement Approval for AKANTIOR® in Spain

AKANTIOR® is anticipated to become available to Spanish patients on 1st August Spain is the first Country in the world to approve the pricing and...

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Saint Herblain (France), July, 11 2025Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).

Valneva annonce la levée de la restriction temporaire de l’Agence européenne des médicaments sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes...

Saint Herblain (France), le 11 juillet 2025Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) allait lever sa restriction temporaire sur la vaccination des personnes âgées de 65 et plus avec le vaccin à dose unique contre le chikungunya IXCHIQ® de Valneva suite à l’achèvement d’une revue complète du vaccin par le comité pour l’évaluation des risques en matière de pharmacovigilance de l’EMA (PRAC).

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on July 8, 2025 (the “Grant Date”), in connection with the commencement of employment.

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

New Bay Area Lyme Foundation Study Reports That Only One-Third of Early Lyme Patients with On-Going Symptoms Followed up with their Healthcare Providers

The new research, published in Frontiers in Medicine, points to the need for greater follow-up from medical professionals to address potential treatment failures.

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Spine Degenerative Disk Disease Treatment Market to Reach USD 39,589.9 Billion by 2032, Growing at a CAGR of 4.39%: Credence Research

PUNE, India, July 9, 2025 /PRNewswire/ -- According to Credence Research, the global Spine Degenerative Disk Disease Treatment Market was valued at USD 22,272.2...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfection